Similar Search Results

The Economics of Prevention in a Post-Managed-Care Environment

Chang, Cyril F.; Waters, Teresa M.; Mirvis, David M. - In: Applied Health Economics and Health Policy 3 (2004) 2, pp. 67-70

Persistent link: https://www.econbiz.de/10005404741

Examining Within-Country Variation of Maternity Costs in the Context of a Multicountry, Multicentre Randomised Controlled Trial

Hutton, Guy; Fox-Rushby, Julia; Mugford, Miranda; … - In: Applied Health Economics and Health Policy 3 (2004) 3, pp. 161-170

Understanding why healthcare costs vary between patients and between health facilities is important in guiding health policy decisions as well as in research. However, there is no comprehensive framework that analysts commonly use for expressing and examining causes of cost variation in the...

Persistent link: https://www.econbiz.de/10005404764

Transferability of Economic Evaluation Results

Antonanzas, Fernando - In: PharmacoEconomics 22 (2004) 13, pp. 827-827

Persistent link: https://www.econbiz.de/10005404772

Healthcare Rationing in Spain: Framework, Descriptive Analysis and Consequences

Rodriguez-Monguio, Rosa; Antonanzas Villar, Fernando - In: PharmacoEconomics 24 (2006) 6, pp. 537-548

This paper describes the main healthcare rationing policies implemented in Spain over the last 2 decades, and analyses the consequences of these policies on the healthcare system, patients, healthcare practitioners, the pharmaceutical industry and policymakers. The primary explicit healthcare...

Persistent link: https://www.econbiz.de/10005404809

Candesartan Cilexetil: A Pharmacoeconomic Review of its Use in Chronic Heart Failure and Hypertension

Plosker, Greg L.; Keam, Susan J. - In: PharmacoEconomics 24 (2006) 12, pp. 1249-1272

The addition of candesartan cilexetil (Atacand(R), Amias(R), Blopress(R), Kenzen(R), Ratacand(R)) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis...

Persistent link: https://www.econbiz.de/10005404816

Time Preferences for Health in Northern Tanzania: An Empirical Analysis of Alternative Discounting Models

Robberstad, Bjarne; Cairns, John - In: PharmacoEconomics 25 (2007) 1, pp. 73-88

Aim: The discounted utility (DU) model has dominated economic evaluation for almost 7 decades, despite the fact that important assumptions of the model are commonly found to be violated. This paper formally explores whether the key assumption of stationarity is violated in a sample of the...

Persistent link: https://www.econbiz.de/10005404868

Resource Use and Cost of Care for Patients Hospitalised with Community Acquired Pneumonia: Impact of Adherence to Infectious Diseases Society of America Guidelines

Orrick, Joanne J.; Segal, Richard; Johns, Thomas E.; … - In: PharmacoEconomics 22 (2004) 11, pp. 751-757

hospitalised with community-acquired pneumonia (CAP) who were treated with preferred antibacterial therapy according to the 1998 … demographic characteristics, pneumonia risk class, resource use (pharmacy, laboratory, radiology, respiratory services, hospital … patients (75.8%) received preferred antibacterials according to the IDSA guidelines. The group treated with preferred …

Persistent link: https://www.econbiz.de/10005404886

Management and Prevention of Diabetic Foot Ulcers and Infections: A Health Economic Review

Chow, Ivy; Lemos, Elkin V.; Einarson, Thomas R. - In: PharmacoEconomics 26 (2008) 12, pp. 1019-1035

compared with prolonged antibacterials, MRI cost $US120 (year 1993 value) more without additional quality-adjusted life …

Persistent link: https://www.econbiz.de/10005404899

Valuing Prevention Through Economic Evaluation: Some Considerations Regarding the Choice of Discount Model for Health Effects with Focus on Infectious Diseases

Bos, Jasper M.; Beutels, Philippe; Annemans, Lieven; … - In: PharmacoEconomics 22 (2004) 18, pp. 1171-1179

In cost-effectiveness analysis, the valuing of costs and health effects over time remains a controversial issue. The debate mostly focuses on whether the discount rates for health and money should be equal and which discounting model and time preferences are most appropriate. In this paper we...

Persistent link: https://www.econbiz.de/10005404911

Long-Term Drug Treatment of GERD: Economic Issues for Formulary Decision Makers

Chan, James; Levin, Theodore R. - In: Disease Management and Health Outcomes 12 (2004) 6, pp. 399-407

Gastroesophageal reflux disease (GERD) is one of the most common disorders of the gastrointestinal tract. Clinical presentation can vary from simple heartburn to erosive esophagitis. Some patients require long-term, possibly life-long, therapy. The cost of treatment is substantial, as patients...

Persistent link: https://www.econbiz.de/10005590164